A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
- 3 March 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 13 (5), 509-516
- https://doi.org/10.1093/neuonc/nor017
Abstract
Romidepsin, a potent histone deacetylase inhibitor, has shown activity in preclinical glioma models. The primary objectives of this trial were to determine the pharmacokinetics of romidepsin in patients with recurrent glioma on enzyme-inducing antiepileptic drugs (EIAEDs) and to evaluate the antitumor efficacy of romidepsin in patients with recurrent glioblastoma who were not receiving EIAEDs. Two dose cohorts were studied in the phase I component of the trial (13.3 and 17.7 mg/m2/d). Patients in the phase II component were treated with intravenous romidepsin at a dosage of 13.3 mg/m2/day on days 1, 8, and 15 of each 28-day cycle. Eight patients were treated on the phase I component. A similar romidepsin pharmacokinetic profile was demonstrated between patients receiving EIAEDs to those not receving EIAEDs. Thirty-five patients with glioblastoma were accrued to the phase II component. There was no objective radiographic response. The median progression-free survival (PFS) was 8 weeks and only 1 patient had a PFS time ≥6 months (PFS6 = 3%). To date, 34 patients (97%) have died, with a median survival duration of 34 weeks. Despite in vitro studies showing that romidepsin is primarily metabolized by CYP3A4, no decrease in exposure to romidepsin was seen in patients receiving potent CYP3A4 inducers. Romidepsin, at its standard dose and schedule, was ineffective for patients with recurrent glioblastomas. ClinicalTrials.gov identifier: NCT00085540.This publication has 29 references indexed in Scilit:
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell LymphomaJournal of Clinical Oncology, 2010
- Identification of Cytochrome P450 Enzymes Involved in the Metabolism of FK228, a Potent Histone Deacetylase Inhibitor, in Human Liver MicrosomesBiological & Pharmaceutical Bulletin, 2005
- A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemiaBlood, 2004
- Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primatesCancer Chemotherapy and Pharmacology, 2004
- Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivoActa Neuropathologica, 2004
- Modulation of p53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228JNCI Journal of the National Cancer Institute, 2002
- Determination of the antitumor agent depsipeptide in plasma by liquid chromatography on serial octadecyl stationary phasesJournal of Chromatography B: Biomedical Sciences and Applications, 1998
- Inhibition and Induction of Cytochrome P450 and the Clinical ImplicationsClinical Pharmacokinetics, 1998
- Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomasThe Lancet, 1995
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990